1.DATABASE construction  n=1,715  Median OS=40.0 months, age: 64+/-10 yrs  Histology (adeno/squamous/large): 50% / 45% / 5%  Stage 1/2/3/4: 63% / 27%

Slides:

Advertisements

Similar presentations

TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.

Advertisements

Microarray GEO – Microarray sets database

Glioblastoma Multiforme (GBM) – Subtype Analysis Lance Parsons.

PROGNOSTIC SIGNIFICANCE OF PRIMARY TUMORAL FDG UPTAKE MEASURED BY PET: Systematic Review and Meta-analysis Ben A. Dwamena, MD.

Emergent Biology Through Integration and Mining Of Microarray Datasets Lance D. Miller GIS Microarray & Expression Genomics.

MammaPrint, the story of the 70-gene profile

References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.

Introduction The goal of translational bioinformatics is to enable the transformation of increasingly voluminous genomic and biological data into diagnostics.

PrognoScan A new database for meta-analysis of the prognostic value of genes 1 Hideaki Mizuno, Kunio Kitada, Kenta Nakai, Akinori Sarai BMC Med Genomics.

Analysis of Molecular and Clinical Data at PolyomX Adrian Driga 1, Kathryn Graham 1, 2, Sambasivarao Damaraju 1, 2, Jennifer Listgarten 3, Russ Greiner.

ONLINE BIOMARKER VALIDATION OF SURVIVAL- ASSOCIATED BIOMARKERS IN BREAST AND OVARIAN CANCER USING MICROARRAY DATA OF 3,862 4,323 PATIENTS Balázs Győrffy.

Sage Bionetworks Mission Sage Bionetworks is a non-profit organization with a vision to create a “commons” where integrative bionetworks are evolved by.

Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.

Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer.

Selection of Patient Samples and Genes for Disease Prognosis Limsoon Wong Institute for Infocomm Research Joint work with Jinyan Li & Huiqing Liu.

Introduction to Affymetrix Microarrays

Controlling FDR in Second Stage Analysis Catherine Tuglus Work with Mark van der Laan UC Berkeley Biostatistics.

Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,

Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide 1 Cereblon Expression Predicts.

Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.

Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.

Overall survival in NSCLC

Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors

Pan-cancer analysis of prognostic genes Jordan Anaya Omnes Res, In this study I have used publicly available clinical and.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

Discussant Slides: Title: Radiosensitivity Index Shows Promise for Predicting Outcomes with Adjuvant Radiation in Resected Pancreatic Cancer Patients Poster.

GEO (Gene Expression Omnibus) Deepak Sambhara Georgia Institute of Technology 21 June, 2006.

Guide to OncoLnc: A new TCGA data portal

Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.

Lung squamous cell carcinoma

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Compassionate People World Class Care

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Prognosis of younger patients in non-small cell lung cancer

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Robert Klein, MS, Catherine.

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Endothelial Ang‐2 upregulation correlates with WHO grading in human gliomas Endothelial Ang‐2 upregulation correlates with WHO grading in human gliomas.

High CDK6 expression predicts poor prognosis in EOC patients

János Fekete, Balázs Győrffy

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.

Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy Number of metastatic lung foci in untreated (control) and.

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

Cumulative mortality risk in patients with 48-h blood urea nitrogen (BUN) levels of ≥8 mg/dl or

Supplementary Figure S1

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Influence of ASGR2 expression on survival.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,

Fig. 1. FAM83H over-expression is associated with poor prognosis of CC

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

1.DATABASE construction  n=1,715  Median OS=40.0 months, age: 64+/-10 yrs  Histology (adeno/squamous/large): 50% / 45% / 5%  Stage 1/2/3/4: 63% / 27% / 10% / 1% 2.META-ANALYSIS of biomarker candidates  Biomarker candidates identified in Pubmed n=22  For each gene the exact conditions in which it was identified have been retrieved, and these have been used as filtering when selecting the patients for the survival analysis.  Of the 22, the best performing genes are: n(1): number of patients in original study, n(2): number of patients in the KM-plotter, HR: hazard ratio, ADE: adenocarcinoma, NSCLC: all non-small-cell lung cancer patients 3.Selected KAPLAN-MEIER plots (table: *) An online tool for the validation of survival-predicting biomarkers in non small-cell lung cancer using microarray data of 1,329 1,715 patients Background and Objective Materials & Methods Results Web addresses Summary Grant support: OTKA PD 83154, PREDICT (EU Health ), KTIA EU_BONUS_ , Alexander von Humboldt-Foundation Grant support: OTKA PD 83154, PREDICT (EU Health ), KTIA EU_BONUS_ , Alexander von Humboldt-Foundation Balázs Győrffy and András Lánczky Research Laboratory for Pediatrics and Nephrology, Hungarian Academy of Sciences and Semmelweis University 1st Dept. of Pediatrics, Budapest, Hungary SymbolReferencen(1)Cohortn(2)HRp value VEGFZhan et al NSCLC e-10 Cyclin EHuang et al NSCLC e-09* ADE e-08 CDK1Zhang et al 2012a2731NSCLC <1e-16* CADM1Botling et al ADE e-12* CDKN2AJin et al NSCLC e-09 CD24Lee et al ADE e-10 ERCC1Simon et al NSCLC e-10 1.DATABASE construction  Repositories: GEO, TCGA, ArrayExpress, caBIG  Platforms: Affymetrix HGU133A, plus2 & A 2.0 arrays  at least 30 patients with survival information  MAS5 normalization + quality control 2.SURVIVAL analysis  Kaplan-Meier plot  „survival” Bioconductor package  Cox univariate + multivariate analysis 3.ONLINE platform  Apache web server on Debian Linux  script developed in PHP  Open access at: 4.META-analysis  Pubmed search of published biomarkers  Best cutoff selection: each percentile (of expression) between the lower and upper quartiles are computed and the best performing threshold is used as the final cutoff in the Cox regression analysis. 1.optimized treatment for non-small cell lung cancer had lead to improved prognosis, but the overall survival is still very short 2.by identifying biomarkers related to survival we can further understand the molecular basis of the disease OBJECTIVE: we present the development of an online available tool suitable for the real-time meta-analysis of published lung cancer microarray datasets to identify biomarkers related to survival  we performed a meta-analysis of survival-associated genes  an integrated database and an online tool for future in silico validation of new candidates has been established Online access: Group homepage: Contact: Cyclin E1CDK1CADM1